Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

India already has a homegrown CAR T-cell therapy, and other regions are exploring their own strategies, including developing them at the point of care.

GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication ...

The US Food and Drug Administration has issued a warning about products containing tianeptine, often called “gas station ...

Q1 2025 Earnings Call Transcript May 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

The U.S. Food and Drug Administration (FDA) has issued a warning to patients and healthcare professionals regarding the use ...

Financial Results As of March 31, 2025, the company’s cash, cash equivalents, and marketable securities were $23.2 million. Total operating expenses for the quarter ended March 31, 2025 were $12.9 ...

California Told Companies to Label Toxic Chemicals. Instead They’re Quietly Dropping Them Businesses are making moves to ...